IFNA2 and neoplasm: Notably, cytokine mRNA triplet with 3:1:1 mass ratio of IL-12, IL-7, and IFN-α exhibited superior anti-tumor activity, with 93.84% TGI at day 18 after the first treatment and 80% survival rate at the end of the study (Figures 5A, B).